San Francisco, CA, United States
San Francisco, CA, United States

Time filter

Source Type

Kellar R.S.,Theregen Inc. | Kellar R.S.,Hill Engineering, LLC | Williams S.K.,Cardiovascular Innovation Institute | Naughton G.K.,Theregen Inc. | And 2 more authors.
Tissue Engineering - Part A | Year: 2011

The current study's purpose was to evaluate the safety and biological effect of a scaffold-based three-dimensional human dermal fibroblast culture (3DFC, also known as Anginera™) to treat chronically ischemic canine hearts. It was hypothesized that treatment with 3DFC would be safe and significantly improve ventricular performance and wall motion. In this study, chronic myocardial ischemia was induced in 40 animals through the surgical placement of an ameroid constrictor. Approximately 30 days after ameroid placement, animals were randomized into four test groups: (1) sham treatment, (2) one unit of acellular 3DFC, (3) one unit of viable 3DFC, and (4) three units of viable 3DFC. Animals were necropsied 30 or 90 days after treatment. Evaluation of the safety endpoint demonstrated the safety of 3DFC at all dosing levels and at both time points. Additionally, parameters of cardiac output, left ventricular ejection fraction, left ventricular end systolic volume index, and systolic wall thickening support the conclusions that 3DFC stimulates a positive biologic effect on ischemic canine hearts. Further, these data support the conclusion that treatment with viable 3DFC improves ventricular performance and ventricular wall motion in chronically ischemic canine hearts 30 days after treatment. © 2011, Mary Ann Liebert, Inc.


Patent
Arizona Board Of Regents and Theregen Inc. | Date: 2012-04-18

Compositions and methods for treating congestive heart failure are provided herein.


Patent
Theregen Inc. | Date: 2012-02-23

Compositions and methods for treating ischemic tissue are provided herein.


Patent
Theregen Inc. | Date: 2010-10-28

Compositions and methods for treating ischemic tissue are provided herein.


Patent
Theregen Inc. | Date: 2011-05-18

The present disclosure provides compositions of three dimensional tissue that can be administered into tissues and organs using minimally invasive methods. The three dimensional tissues elaborate a repertoire of growth factors that facilitate repair or regeneration of damaged tissues and organs.


Patent
Theregen Inc. | Date: 2011-03-02

Compositions and methods for treating congestive heart failure are provided herein.


The present invention relates to a method for promoting blood vessel formation in tissues and organs. In particular, the method relates to implantation or attachment of an engineered three-dimensional stromal tissue to promote endothelialization and angiogenesis in the heart and related tissues. The three-dimensional stromal tissue of the present invention may be used in a variety of applications including, but not limited to, promoting repair of and regeneration of damaged cardiac muscle, promoting vascularization and healing during cardiac surgery, promoting blood vessel formation at anastomosis sites, and promoting vascularization and repair of damaged skeletal muscle, smooth muscle or connective tissue.


Patent
Theregen Inc. | Date: 2010-09-02

The present disclosure provides compositions of three dimensional tissue that can be administered into tissues and organs using minimally invasive methods. The three dimensional tissues elaborate a repertoire of growth factors that facilitate repair or regeneration of damaged tissues and organs.

Loading Theregen Inc. collaborators
Loading Theregen Inc. collaborators